Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Esomeprazole 40 mg administered intravenously has similar safety and efficacy profiles to the oral formulation in patients with erosive esophagitis
Digestion, Volume 70, No. 4, Year 2004
Notification
URL copied to clipboard!
Description
Background/Aims: An intravenous formulation of esomeprazole has been developed for use in patients where oral administration is not appropriate. This study evaluated safety after 1 and 4 weeks, and efficacy after 4 weeks' esomeprazole 40 mg once daily treatment, administered via an intravenous injection, intravenous infusion or orally, in patients with erosive esophagitis. Methods: In this double-blind, multi-centre study, patients with endoscopically confirmed erosive esophagitis (Los Angeles grade A-D) were randomized to receive 1 week's treatment of esomeprazole 40 mg once daily, via a 3-min injection, a 30-min infusion or orally, followed by 3 weeks of open treatment with oral esomeprazole 40 mg once daily. Safety variables were evaluated following 1 and 4 weeks' esomeprazole treatment. Healing rates at 4 weeks were estimated. Results: Intravenous and oral esomeprazole were equally well tolerated during the first week, and after 4 weeks' treatment. The 3 treatment groups showed similar levels of healing following 4 weeks' treatment with esomeprazole (injection + oral: 79.7%; infusion + oral: 80.2%; oral alone: 82.6%). Conclusions: Esomeprazole 40 mg administered via an intravenous injection, intravenous infusion or orally administered for 1 week, followed by 3 weeks of oral dosing, is well tolerated and provides effective healing of erosive esophagitis. Copyright © 2004 S. Karger AG.
Authors & Co-Authors
Schneider, Herbert
South Africa, Johannesburg
Milpark Hospital
van Rensburg, Christoffel Johannes
South Africa, Tygerberg
Tygerberg Hospital
Schmidt, S.
South Africa, Cape Town
City Medical Chambers
Aboo, Nazimuddin
South Africa, Durban
Parklands Hospital
Mäkelä, Heli
Sweden, Sodertalje
Astrazeneca Sweden
Nauclér, Emma C.
Sweden, Sodertalje
Astrazeneca Sweden
Hallerbäck, Bengt
Sweden, Sodertalje
Astrazeneca Sweden
Svedberg, Lars Erik
Sweden, Sodertalje
Astrazeneca Sweden
Statistics
Citations: 13
Authors: 8
Affiliations: 5
Identifiers
Doi:
10.1159/000083717
ISSN:
00122823
Research Areas
Disability
Health System And Policy